Cargando…

Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas

Cystic fibrosis (CF) is a genetic disorder in which frequent pulmonary infections develop secondarily. One of the major pulmonary pathogens colonizing the respiratory tract of CF patients and causing chronic airway infections is Pseudomonas aeruginosa. Although tobramycin was initially effective aga...

Descripción completa

Detalles Bibliográficos
Autores principales: Sans-Serramitjana, Eulalia, Jorba, Marta, Fusté, Ester, Pedraz, José Luis, Vinuesa, Teresa, Viñas, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620626/
https://www.ncbi.nlm.nih.gov/pubmed/28672861
http://dx.doi.org/10.3390/microorganisms5030035
_version_ 1783267627397808128
author Sans-Serramitjana, Eulalia
Jorba, Marta
Fusté, Ester
Pedraz, José Luis
Vinuesa, Teresa
Viñas, Miguel
author_facet Sans-Serramitjana, Eulalia
Jorba, Marta
Fusté, Ester
Pedraz, José Luis
Vinuesa, Teresa
Viñas, Miguel
author_sort Sans-Serramitjana, Eulalia
collection PubMed
description Cystic fibrosis (CF) is a genetic disorder in which frequent pulmonary infections develop secondarily. One of the major pulmonary pathogens colonizing the respiratory tract of CF patients and causing chronic airway infections is Pseudomonas aeruginosa. Although tobramycin was initially effective against P. aeruginosa, tobramycin-resistant strains have emerged. Among the strategies for overcoming resistance to tobramycin and other antibiotics is encapsulation of the drugs in nanoparticles. In this study, we explored the antimicrobial activity of nanoencapsulated tobramycin, both in solid lipid nanoparticles (SLN) and in nanostructured lipid carriers (NLC), against clinical isolates of P. aeruginosa obtained from CF patients. We also investigated the efficacy of these formulations in biofilm eradication. In both experiments, the activities of SLN and NLC were compared with that of free tobramycin. The susceptibility of planktonic bacteria was determined using the broth microdilution method and by plotting bacterial growth. The minimal biofilm eradication concentration (MBEC) was determined to assess the efficacy of the different tobramycin formulations against biofilms. The activity of tobramycin-loaded SLN was less than that of either tobramycin-loaded NLC or free tobramycin. The minimum inhibitory concentration (MIC) and MBEC of nanoencapsulated tobramycin were slightly lower (1–2 logs) than the corresponding values of the free drug when determined in tobramycin-susceptible isolates. However, in tobramycin-resistant strains, the MIC and MBEC did not differ between either encapsulated form and free tobramycin. Our results demonstrate the efficacy of nanoencapsulated formulations in killing susceptible P. aeruginosa from CF and from other patients.
format Online
Article
Text
id pubmed-5620626
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-56206262017-10-03 Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas Sans-Serramitjana, Eulalia Jorba, Marta Fusté, Ester Pedraz, José Luis Vinuesa, Teresa Viñas, Miguel Microorganisms Article Cystic fibrosis (CF) is a genetic disorder in which frequent pulmonary infections develop secondarily. One of the major pulmonary pathogens colonizing the respiratory tract of CF patients and causing chronic airway infections is Pseudomonas aeruginosa. Although tobramycin was initially effective against P. aeruginosa, tobramycin-resistant strains have emerged. Among the strategies for overcoming resistance to tobramycin and other antibiotics is encapsulation of the drugs in nanoparticles. In this study, we explored the antimicrobial activity of nanoencapsulated tobramycin, both in solid lipid nanoparticles (SLN) and in nanostructured lipid carriers (NLC), against clinical isolates of P. aeruginosa obtained from CF patients. We also investigated the efficacy of these formulations in biofilm eradication. In both experiments, the activities of SLN and NLC were compared with that of free tobramycin. The susceptibility of planktonic bacteria was determined using the broth microdilution method and by plotting bacterial growth. The minimal biofilm eradication concentration (MBEC) was determined to assess the efficacy of the different tobramycin formulations against biofilms. The activity of tobramycin-loaded SLN was less than that of either tobramycin-loaded NLC or free tobramycin. The minimum inhibitory concentration (MIC) and MBEC of nanoencapsulated tobramycin were slightly lower (1–2 logs) than the corresponding values of the free drug when determined in tobramycin-susceptible isolates. However, in tobramycin-resistant strains, the MIC and MBEC did not differ between either encapsulated form and free tobramycin. Our results demonstrate the efficacy of nanoencapsulated formulations in killing susceptible P. aeruginosa from CF and from other patients. MDPI 2017-06-26 /pmc/articles/PMC5620626/ /pubmed/28672861 http://dx.doi.org/10.3390/microorganisms5030035 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sans-Serramitjana, Eulalia
Jorba, Marta
Fusté, Ester
Pedraz, José Luis
Vinuesa, Teresa
Viñas, Miguel
Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas
title Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas
title_full Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas
title_fullStr Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas
title_full_unstemmed Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas
title_short Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas
title_sort free and nanoencapsulated tobramycin: effects on planktonic and biofilm forms of pseudomonas
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620626/
https://www.ncbi.nlm.nih.gov/pubmed/28672861
http://dx.doi.org/10.3390/microorganisms5030035
work_keys_str_mv AT sansserramitjanaeulalia freeandnanoencapsulatedtobramycineffectsonplanktonicandbiofilmformsofpseudomonas
AT jorbamarta freeandnanoencapsulatedtobramycineffectsonplanktonicandbiofilmformsofpseudomonas
AT fusteester freeandnanoencapsulatedtobramycineffectsonplanktonicandbiofilmformsofpseudomonas
AT pedrazjoseluis freeandnanoencapsulatedtobramycineffectsonplanktonicandbiofilmformsofpseudomonas
AT vinuesateresa freeandnanoencapsulatedtobramycineffectsonplanktonicandbiofilmformsofpseudomonas
AT vinasmiguel freeandnanoencapsulatedtobramycineffectsonplanktonicandbiofilmformsofpseudomonas